Rectal Cancer
985
183
231
366
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
85 trials with published results (9%)
Research Maturity
366 completed trials (37% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.7%
66 terminated out of 985 trials
84.7%
-1.9% vs benchmark
8%
80 trials in Phase 3/4
23%
85 of 366 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 366 completed trials
Clinical Trials (985)
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
Distance-Based Exercise to Preserve Function and Prevent Disability
Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer
The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
PRE-ISPY Phase I/II Oncology Platform Program
A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer
Tamsulosin for Early Catheter Removal After Rectal Cancer Surgery
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
RCT of Mobile Apps & FitBit v. Usual Care
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study
ABCSG R07 Rectal Cancer Registry
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)